Indian Pharma Market Grew 8.5% In December With Covid-19 Impact Behind: Anand Rathi
Favipiravir, the antiviral medication being manufactured in Russia. (Photographer: Andrey Rudakov/Bloomberg)

Indian Pharma Market Grew 8.5% In December With Covid-19 Impact Behind: Anand Rathi


BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Anand Rathi Report

The Indian pharma market seems to have recovered from the Covid-19 impact as growth in acute therapies has rebounded after a brief nine months.

The IPM grew 8.5% in December (6.4% in Q3 FY21, 0.9% year-to-date). Acute therapies grew 6%; chronic/sub-chronic, 10.9%/ 9.7%.

Key acute therapies anti-infectives and gastro did well as hospitals are seeing more patients. chronic therapies cardiac, diabetes and vitamins continue to boost growth for the sector.

Dec volumes were up 0.3% (against a 7% drop in November 2020) while prices were increased 5%, 3.1% coming from launches.

The volume decline has now largely been arrested and volume growth should now be in healthy single digits.

Click on the attachment to read the full report:

Anand Rathi IPM Update.pdf


This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

BQ Install

Bloomberg Quint

Add BloombergQuint App to Home screen.